GSK Oncology Mega-Acquisition
GSK's $10.6 billion acquisition of Nuvalent marks its largest deal in eight years, signaling aggressive re-entry into oncology and triggering a wave of repricing across cancer-focused biotech peers including Incyte and Johnson & Johnson as investors reassess competitive positioning and M&A premium potential across the sector.
stocks
Related Assets
| Asset | Price | 24h Change | Sector |
|---|---|---|---|
GSKGSK plc | $52.92 | +3.32% | general |
GILDGilead Sciences Inc | $125.86 | +3.53% | healthcare |
JNJJohnson & Johnson | $238.53 | -0.15% | healthcare |
LLYEli Lilly and Company | $1,166.79 | +0.94% | healthcare |
Latest Market Pulses
GSK's $11B Nuvalent Acquisition: Leverage Scenarios, Merger-Arb Spreads & Sector Re-Rating
GSK is acquiring Nuvalent for $11B cash at a 40% premium, targeting two late-stage FDA-reviewed lung cancer drugs; GSK CFD traders face binary FDA catalysts in Sep/Nov 2026, while Nuvalent is now a capped merger-arb instrument near $124.
GSK
2026-06-11
Related Sectors
Ready to trade?
Trade assets related to the GSK Oncology Mega-Acquisition theme with up to 2,000x leverage on CoinUnited.io.
Start Trading on CoinUnited.io →